AR059026A1 - Derivados triazolicos como ligandos analogos de ghrelina de receptores secretagogos de la hormona de crecimiento.composiciones farmaceuticas - Google Patents
Derivados triazolicos como ligandos analogos de ghrelina de receptores secretagogos de la hormona de crecimiento.composiciones farmaceuticasInfo
- Publication number
- AR059026A1 AR059026A1 ARP060103531A ARP060103531A AR059026A1 AR 059026 A1 AR059026 A1 AR 059026A1 AR P060103531 A ARP060103531 A AR P060103531A AR P060103531 A ARP060103531 A AR P060103531A AR 059026 A1 AR059026 A1 AR 059026A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- arylalkyl
- aryl
- group
- heteroarylalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
Abstract
Derivados triazolicos como ligandos análogos de ghrelina de receptores secretagogos de la hormona de crecimiento de acuerdo con la formula (1) que son utiles en el tratamiento o la profilaxis de afecciones fisiologicas y/o patofisiologicas en mamíferos, con preferencia humanos, que están mediadas por los receptores GHS. Además antagonistas del receptor GHS y agonistas que pueden usarse para la modulacion de estos receptores y son utiles para tratar las afecciones anteriores, en particular retraso en el crecimiento, caquexia, regulacion a corto, mediano y/o largo plazo del balance de energía; regulacion a corto, mediano y/o largo plazo (estimulacion y/o inhibicion) de la ingesta de alimentos; adipogénesis, adiposidad y/u obesidad; aumento y/o reduccion del peso corporal; diabetes, diabetes tipo I, diabetes tipo II, proliferacion de células tumorales; inflamacion, efectos inflamatorios, íleo gástrico post-operatorio, íleo post-operatorio y/o gasterectomía (terapia de reemplazo de ghrelina)ö. Reivindicacion 1: El uso de un compuesto de acuerdo con la formula (1) donde R1 y R2 se seleccionan, en forma independiente uno del otro, del grupo que consiste en ôátomo de hidrogeno, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfoniloö que están sustituidos en forma opcional en el grupo alquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y/o heterociclilalquilo por hasta 3 sustituyentes seleccionados en forma independiente del grupo que consiste en ôhalogeno, -F, -CI, -Br, -I, -N3, -CN, -NR7R8, - OH, -NO2, alquilo, arilo, arilalquilo, -O-alquilo, -O-arilo, -O-arilalquiloö; y con preferencia se seleccionan del grupo que consiste en ôalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquiloö en forma opcional están sustituidos por hasta 3 sustituyentes seleccionados en forma independiente del grupo que consiste en ôhalogeno, -F, -CI, -Br, -I, -N3, -CN, -NR7R8, -OH, -NO2, alquilo, arilo, arilalquilo, -O-alquilo, -O-arilo, -O-arilalquiloö; uno de los radicales R3 y R4 es un átomo de hidrogeno, mientras que el otro radical se selecciona del grupo que consiste en ôátomo de hidrogeno, alquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -alquil-O-arilo, -alquil-O-arilalquilo, -alquil-O- heteroarilo, -alquil-O-heteroarilalquilo, -alquil-O-heterociclilo, alquil-O-heterociclilalquilo, -alquil-CO-arilo, -alquil-CO-arilalquilo, alquil-CO-heteroariIo, alquil-CO-heteroarilalquilo, -alquil-CO-heterociclilo, -alquil-CO-heterociclilalquilo, - alquil-C(O)O-arilo, -alquil-C(O)O-arilalquilo, -alquil-C(O)O-heteroarilo, -alquil-C(O)O-heteroarilalquilo, -alquil-C(O)O-heterociclilo, alquil-C(O)O-heterociclilalquilo, -alquil-CO-NH2, - alquil-CO-OH, -alquil-NH2, -alquil-NH-C(NH)-NH2, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo, alquil-S-alquilo, alquil-S-Hö que están sustituidos en forma opcional en el grupo arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y/o heterociclilalquilo por hasta 3 sustituyentes seleccionados en forma independiente del grupo que consiste en ôhalogeno, -F, -CI, -Br, -I, -N3, -CN, -NR7R8, -OH, -NO2, alquilo, arilo, arilalquilo, -O-alquilo, -O-arilo, -O-arilalquiloö y con preferencia se seleccionan del grupo que consiste en ôarilalquilo, heteroarilalquilo, heterociclilalquilo, -alquil-O-arilo, -alquil-O-arilalquilo, -alquil-O-heteroarilo, -alquil-O-heteroarilalquilo, -alquil-O-heterociclilo, alquil-O-heterociclilalquilo, -alquil-CO-arilo, -alquil-CO- arilalquilo, alquil-CO-heteroariIo, alquil-CO-heteroarilalquilo, -alquil-CO-heterociclilo, -alquil-CO-heterociclilalquilo, -alquil-C(O)O-arilo, -alquil-C(O)O-arilalquilo, -alquil-C(O)O-heteroarilo, -alquil-C(O)O-heteroarilalquilo, -alquil-C(O)O- heterociclilo, alquil-C(O)O-heterociclilalquilo, -alquil-CO-NH2, - alquil-CO-OH, -alquil-NH2, -alquil-NH-C(NH)-NH2ö, en forma opcional están sustituidos en el grupo arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo y/o heterociclilalquilo por hasta 3 sustituyentes seleccionados en forma independiente del grupo que consiste en ôhalogeno, -F, -CI, -Br, -I, -N3, -CN, -NR7R8, -OH, -NO2, alquilo, arilo, arilalquilo, -O-alquilo, -O-arilo, -O-arilalquiloö; R5 se selecciona del grupo que consiste en ôátomo de hidrogeno, alquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, -CO-alquilo, -CO-cicloalquilo, -CO-cicloalquilalquilo, -CO- arilo, -CO-arilalquilo, -CO-heteroarilo, -CO-heteroarilalquilo, -CO-heterociclilo, -CO-heterociclilalquilo, -CO-C*(R9R10)-NH2, -CO-CH2-C*(R9R10)-NH2, -CO-C*(R9R10)-CH2-NH2, alquilsulfonilo, arilsulfonilo, arilalquilsulfoniloö que están sustituidos en forma opcional por hasta 3 sustituyentes seleccionados en forma independiente del grupo que consiste en ôhalogeno, -F, -CI, -Br, -I, -N3, -CN, -NR7R8, -OH, -NO2, alquilo, arilo, arilalquilo, -O-alquilo, -O-arilo, -O-arilalquiloö y con preferencia se selecciona del grupo que consiste en ôátomo de hidrogeno, -CO-alquilo, -CO-cicloalquilo, -CO-arilo, -CO-heteroarilo, -CO-arilalquilo, -CO- heteroarilalquilo, -CO-heterociclilo, -CO-C*(R9R10)-NH2, -CO-CH2-C*(R9R10)-NH2, -CO-C*(R9R10)-CH2-NH2, en forma opcional están sustituidos por hasta 3 sustituyentes seleccionados en forma independiente del grupo que consiste en ôhalogeno, -F, -CI, -Br, -I, -N3, -CN, -NR7R8, -OH, -NO2, alquilo, arilo, arilalquilo, -O-alquilo, -O-arilo, -O-arilalquiloö; R6 se selecciona del grupo que consiste en ôátomo de hidrogeno, alquilo, cicloalquilo, cicloalquilalquiloö y con preferencia es un átomo de hidrogeno; R7 y R8 se seleccionan, en forma independiente uno del otro, del grupo que consiste en ô átomo de H, alquilo, cicloalquilo, cicloalquilalquiloö y con preferencia son un átomo de H; R9 y R10 se seleccionan, en forma independiente uno del otro, del grupo que consiste en ôátomo de hidrogeno, alquilo, cadena lateral de alfa-aminoácido natural, cadena lateral de alfa-aminoácido no naturalö y con preferencia se seleccionan del grupo que consiste en ôátomo de hidrogeno, alquiloö; m es 0, 1 o 2 y con preferencia es 0; y * significa un átomo de carbono de configuracion R o S cuando es quiral; para la fabricacion de un medicamento para el tratamiento o la profilaxis de afecciones fisiologicas y/o patofisiologicas en mamíferos que están mediadas por los receptores GHS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70794105P | 2005-08-15 | 2005-08-15 | |
EP05017732A EP1757290A1 (en) | 2005-08-16 | 2005-08-16 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
US78754306P | 2006-03-31 | 2006-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059026A1 true AR059026A1 (es) | 2008-03-12 |
Family
ID=35589641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103531A AR059026A1 (es) | 2005-08-15 | 2006-08-11 | Derivados triazolicos como ligandos analogos de ghrelina de receptores secretagogos de la hormona de crecimiento.composiciones farmaceuticas |
Country Status (12)
Country | Link |
---|---|
US (2) | US7829724B2 (es) |
EP (2) | EP1757290A1 (es) |
JP (1) | JP5284091B2 (es) |
KR (1) | KR101050974B1 (es) |
CN (1) | CN101272782B (es) |
AR (1) | AR059026A1 (es) |
AU (1) | AU2006281594B2 (es) |
BR (1) | BRPI0614581A2 (es) |
CA (1) | CA2620280C (es) |
MX (1) | MX2008002089A (es) |
TW (1) | TWI432417B (es) |
WO (1) | WO2007020013A2 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8143425B2 (en) * | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
TW200736234A (en) * | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
ES2558928T3 (es) | 2007-01-31 | 2016-02-09 | Dana-Farber Cancer Institute, Inc. | Péptidos p53 estabilizados y usos de los mismos |
EP1958631A1 (en) * | 2007-02-14 | 2008-08-20 | AEterna Zentaris GmbH | Novel triazole derivatives as ligands of G-protein coupled receptors |
US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
WO2008141189A1 (en) * | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
RU2009146049A (ru) * | 2007-05-14 | 2011-06-20 | Сюзанне Л. ДИКСОН (SE) | Новый метод лечения зависимости от химических средств |
TW200916113A (en) * | 2007-08-08 | 2009-04-16 | Sod Conseils Rech Applic | Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue |
EP2103602A1 (en) | 2008-03-17 | 2009-09-23 | AEterna Zentaris GmbH | Novel 1,2,4-triazole derivatives and process of manufacturing thereof |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
CA2750699C (en) | 2009-02-27 | 2015-12-29 | Raqualia Pharma Inc. | Oxyindole derivatives with motilin receptor agonistic activity |
WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP2013535514A (ja) | 2010-08-13 | 2013-09-12 | エイルロン セラピューティクス,インコーポレイテッド | ペプチド模倣大環状分子 |
EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
CN104159595A (zh) | 2012-02-15 | 2014-11-19 | 爱勒让治疗公司 | 拟肽大环化合物 |
WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
MX2015005244A (es) | 2012-11-01 | 2015-07-14 | Aileron Therapeutics Inc | Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos. |
WO2014110298A1 (en) * | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
US9340578B2 (en) * | 2013-07-15 | 2016-05-17 | Syracuse University | Inhibitors targeting human ghrelin O-acyltransferase |
EP3083564B1 (en) | 2013-12-20 | 2018-07-11 | Novartis AG | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
BR112017019738A2 (pt) | 2015-03-20 | 2018-05-29 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
AU2020325705A1 (en) * | 2019-08-05 | 2022-03-03 | Polyplus Transfection | Compositions for transfecting a nucleic acid molecule into a cell comprising heterocyclic compounds grafted to a cationic polymer, and their applications |
US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
CN113512032B (zh) * | 2021-04-05 | 2023-08-04 | 合肥工业大学 | 一种噁二唑硫醚衍生物及其制备方法和应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
DE68922602T2 (de) | 1988-01-28 | 1995-12-07 | Polygen Holding Corp | Polypeptide mit hormonwachstumsbefreiender wirkung. |
WO1993009095A1 (en) | 1991-10-30 | 1993-05-13 | Fisons Corporation | 2-heterocyclicethylamine derivatives and their use as pharmaceuticals |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
WO1995014666A1 (en) | 1993-11-24 | 1995-06-01 | Merck & Co., Inc. | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
US5703092A (en) | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
ATE424412T1 (de) | 1995-12-22 | 2009-03-15 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
WO1997044042A1 (en) | 1996-05-22 | 1997-11-27 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
HRP980093A2 (en) | 1997-02-28 | 1998-12-31 | Lilly Co Eli | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds |
WO1998058947A1 (en) | 1997-06-25 | 1998-12-30 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
US6506782B1 (en) | 1998-02-27 | 2003-01-14 | Athena Neurosciences, Inc. | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
TR200100149T2 (tr) | 1998-07-06 | 2001-10-22 | Bristol-Myers Squibb Company | Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler |
US6194578B1 (en) | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
RU2240998C2 (ru) | 1998-12-04 | 2004-11-27 | Бристол-Маерс Сквибб Компани | Производные 3-замещенного 4-арилхинолин-2-она в качестве модуляторов калиевых каналов |
US6525203B1 (en) | 1999-03-12 | 2003-02-25 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US6518292B1 (en) | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
ES2248084T3 (es) | 1999-06-14 | 2006-03-16 | Eli Lilly And Company | Inhibidores de serinproteasa. |
AU779426B2 (en) | 1999-11-15 | 2005-01-27 | Janssen Pharmaceutica N.V. | Triazoles as farnesyl transferase inhibitors |
US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
EP1149583A3 (en) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
DOP2001000154A (es) | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
US6683191B2 (en) | 2000-06-05 | 2004-01-27 | Ortho-Mcneil Pharmaceuticals, Inc. | Method for synthesis of substituted azole libraries |
US6951948B2 (en) | 2000-06-05 | 2005-10-04 | Ortho-Mcneil Pharmaceutical, Inc. | Method for synthesis of substituted azole libraries |
DE60128494T2 (de) | 2000-06-13 | 2008-01-17 | Zentaris Gmbh | Verbindungen zur Stimulation der Sekretion von Wachstumshormonen |
IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
SE0102640D0 (sv) | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
SE0102639D0 (sv) | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
JP4562394B2 (ja) | 2001-12-18 | 2010-10-13 | アリゼ、ファルマ、エスアーエス | 非アシル化グレリンを含む医薬組成物およびその治療的使用 |
MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
AU2003293376A1 (en) | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
WO2004089297A2 (en) | 2003-04-02 | 2004-10-21 | Suntory Pharmaceutical Research Laboratories, Llc | Compounds and methods for treatment of thrombosis |
EP1631560A2 (en) | 2003-04-25 | 2006-03-08 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
JP2008545801A (ja) * | 2005-06-10 | 2008-12-18 | エリクシアー ファーマシューティカルズ, インコーポレイテッド | スルホンアミド化合物およびその使用 |
-
2005
- 2005-08-16 EP EP05017732A patent/EP1757290A1/en not_active Withdrawn
-
2006
- 2006-08-11 KR KR1020087003755A patent/KR101050974B1/ko active IP Right Grant
- 2006-08-11 TW TW095129659A patent/TWI432417B/zh not_active IP Right Cessation
- 2006-08-11 US US11/502,473 patent/US7829724B2/en active Active
- 2006-08-11 AR ARP060103531A patent/AR059026A1/es not_active Application Discontinuation
- 2006-08-11 JP JP2008526415A patent/JP5284091B2/ja not_active Expired - Fee Related
- 2006-08-11 WO PCT/EP2006/007945 patent/WO2007020013A2/en active Application Filing
- 2006-08-11 CN CN2006800352875A patent/CN101272782B/zh active Active
- 2006-08-11 EP EP06776764.0A patent/EP1915149B1/en active Active
- 2006-08-11 BR BRPI0614581-7A patent/BRPI0614581A2/pt not_active Application Discontinuation
- 2006-08-11 CA CA2620280A patent/CA2620280C/en active Active
- 2006-08-11 MX MX2008002089A patent/MX2008002089A/es active IP Right Grant
- 2006-08-11 AU AU2006281594A patent/AU2006281594B2/en not_active Ceased
-
2010
- 2010-09-13 US US12/880,774 patent/US8710089B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1915149B1 (en) | 2018-10-10 |
BRPI0614581A2 (pt) | 2011-04-05 |
US20100331343A1 (en) | 2010-12-30 |
AU2006281594B2 (en) | 2011-07-14 |
WO2007020013A2 (en) | 2007-02-22 |
EP1757290A1 (en) | 2007-02-28 |
CN101272782A (zh) | 2008-09-24 |
WO2007020013A3 (en) | 2007-04-19 |
EP1915149A2 (en) | 2008-04-30 |
US7829724B2 (en) | 2010-11-09 |
KR20080059145A (ko) | 2008-06-26 |
CN101272782B (zh) | 2012-03-14 |
MX2008002089A (es) | 2009-02-25 |
CA2620280A1 (en) | 2007-02-22 |
US20070208061A2 (en) | 2007-09-06 |
JP5284091B2 (ja) | 2013-09-11 |
US8710089B2 (en) | 2014-04-29 |
AU2006281594A1 (en) | 2007-02-22 |
KR101050974B1 (ko) | 2011-07-26 |
TWI432417B (zh) | 2014-04-01 |
JP2009504697A (ja) | 2009-02-05 |
US20070037857A1 (en) | 2007-02-15 |
TW200804312A (en) | 2008-01-16 |
CA2620280C (en) | 2015-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059026A1 (es) | Derivados triazolicos como ligandos analogos de ghrelina de receptores secretagogos de la hormona de crecimiento.composiciones farmaceuticas | |
AR083160A1 (es) | Derivados de triazol con mejor actividad de receptor y propiedades de biodisponibilidad como antagonistas de ghrelina de receptores secretagogos de hormona de crecimiento | |
CY1118096T1 (el) | Ρυθμιστες υποδοχεα οπιοειδους | |
PE20070341A1 (es) | Derivados de pirrol como moduladores del receptor de progesterona | |
PE20170084A1 (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4-9(10)-dien-11-arilo como antagonistas de progesterona y procedimientos para su preparacion | |
SI1786790T1 (sl) | Derivati oksazola kot agenti histamin h3 receptorja, priprava in terapevtska uporaba | |
AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
CO5690599A2 (es) | Derivados de 3-(4-aminofenil) tienopirimid-4-ona como antagonistas mch r1 para el tratamiento de obesidad, diabetes, depresion y ansiedad | |
CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
MY146924A (en) | Substituted imidazoheterocycles | |
AR036596A1 (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1 | |
BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
RU2009148336A (ru) | Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2) | |
PE20060648A1 (es) | Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
ES2929799T3 (es) | Compuestos que contienen resto de 2-oxo-1,3,4-tiadiazinan-3-ilo con actividad agonista del receptor EP4 | |
CY1108752T1 (el) | Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα | |
BRPI0814382A2 (pt) | Composto, uso do composto, e, composição farmacêutica | |
MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
PE20091811A1 (es) | DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1 | |
RU2007141578A (ru) | 2-аминокарбонилзамещенные пиперазины или диазациклические соединения в качестве модуляторов ингибитора белка апоптоза (иап) | |
PE20140610A1 (es) | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |